Patents Assigned to Pfizer
  • 2-amino pyrimidine compounds as potent HSP-90 inhibitors
    Patent number: 8080556
    Abstract: The present invention is directed to compounds of formula (I), or pharmaceutically acceptable salts thereof, their synthesis, and their use as HSP-90 inhibitors.
    Type: Grant
    Filed: August 4, 2009
    Date of Patent: December 20, 2011
    Assignee: Pfizer Inc.
    Inventors: Pei-Pei Kung, Jerry Jialun Meng
  • Triazolopyridinylsulfanyl derivatives as P38 map kinase inhibitors
    Patent number: 8076356
    Abstract: A compound of formula (I), or a pharmaceutical acceptable salt and/or solvate (including hydrate) thereof; and the use of a compound of formula (I) in the treatment of a TNF-mediated disease, disorder, or condition, or a p38-mediated disease, disorder, or condition, in particular the allergic and non-allergic airways diseases, more particularly obstructive or inflammatory airways diseases, preferably chronic obstructive pulmonary disease.
    Type: Grant
    Filed: February 16, 2009
    Date of Patent: December 13, 2011
    Assignee: Pfizer Inc.
    Inventors: John Paul Mathias, David Simon Millan, Russell Andrew Lewthwaite, Christopher Phillips
  • CONJUGATES FOR THE PREVENTION OR TREATMENT OF NICOTINE ADDICTION
    Publication number: 20110300174
    Abstract: The present invention relates in part to nicotine-derived hapten-carrier conjugates of the formula (III): wherein m, n, W, -(spacer)-, X* and Y are as defined in the description. In certain embodiments, said nicotine-derived hapten-carrier conjugates can be used to prepare vaccines for the treatment and/or prevention of nicotine addiction.
    Type: Application
    Filed: June 2, 2011
    Publication date: December 8, 2011
    Applicant: Pfizer Vaccines LLC
    Inventors: Alan Daniel BROWN, Heather Lynn DAVIS, David P. GERVAIS, Lyn Howard JONES, James R. MERSON, David Cameron PRYDE, David R. STEAD, Michael J. MCCLUSKIE, Jennifer Marie THORN, Paul Robert MEHELIC, Parag Ashok KOLHE, Keshab BHATTACHARYA, Jari Ilmari FINNEMAN, Erin Kristen PARSONS, Nickolas ANASTASIOU
  • Novel Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-beta,delta-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-[(Phenylmino)Carbonyl]-1H-Pyrrole-1-Heptanoic Acid Calcium Salt (2:1)
    Publication number: 20110301358
    Abstract: Novel forms of [R—(R*,R*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt designated Form XX, Form XXI, Form XXII, Form XXIII, Form XXIV, Form XXVV, Form XXVI, Form XXVII, Form XXVIII, Form XXIX, and Form XXX, characterized by their X-ray powder diffraction, solid-state NMR, and/or Raman spectroscopy are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia (BPII) and Alzheimer's disease.
    Type: Application
    Filed: August 22, 2011
    Publication date: December 8, 2011
    Applicant: Pfizer Inc.
    Inventors: Joseph F. Krzyzaniak, George M. Laurence, Aeri Park, Kevin J. Quackenbush, Marie L. Reynolds, Peter R. Rose, Timothy A. Woods
  • Substituted pyrazinone amides useful for activation of glucokinase
    Patent number: 8071606
    Abstract: The present invention provides compounds of Formula (I) that act as glucokinase activators; pharmaceutical compositions thereof; and methods of treating diseases, disorders, or conditions mediated by glucokinase. The variables R1, R2, R3 and R4 are as described herein.
    Type: Grant
    Filed: January 20, 2010
    Date of Patent: December 6, 2011
    Assignee: Pfizer Inc.
    Inventors: John William Benbow, Jeffrey Allen Pfefferkorn
  • PYRROLO[2,3-D]PYRIMIDINE COMPOUNDS
    Publication number: 20110294826
    Abstract: Described herein are pyrrolo[2,3-d]pyrimidine compounds, their use as Janus Kinase (JAK) inhibitors, pharmaceutical compositions containing these compounds, and methods for their preparation.
    Type: Application
    Filed: December 10, 2010
    Publication date: December 1, 2011
    Applicant: Pfizer Inc.
    Inventors: Jin Xie, Michele Ann Promo, Eric Jon Jacobsen, Horng-Chih Huang, Todd M. Maddux
  • HIGH DOSAGE DORAMECTIN FORMULATION
    Publication number: 20110294751
    Abstract: Veterinary compositions which provide a high-dose of doramectin or a high-dose veterinary combination composition which comprises doramectin and one or more other antiparasitic agents is disclosed. The compositions provide both antiparasitic efficacy and a significantly reduced withhold time.
    Type: Application
    Filed: February 2, 2010
    Publication date: December 1, 2011
    Applicant: PFIZER INC.
    Inventors: Alvimar Jose da Costa, Stephen Lee Secreast, Rodrigo Valarelli
  • IMMUNOGENIC LHRH COMPOSITIONS AND METHODS RELATING THERETO
    Publication number: 20110293647
    Abstract: The present invention relates generally to an immunogenic LHRH composition and more particularly to an immunogenic LHRH composition comprising a LHRH C-terminal fragment of at least five amino acids. The present invention is useful, inter alia, as a prophylactic and/or therapeutic agent for the modification of fertility and behaviour patterns of animals, the achievement of livestock production gains such as increasing growth, decreasing feed conversion ratios or the control of unwanted organoleptic characteristics or the treatment of disorders of the reproductive organs.
    Type: Application
    Filed: June 23, 2011
    Publication date: December 1, 2011
    Applicant: Pfizer Inc.
    Inventor: Michael Kerin McNamara
  • Pyrrolopyrazole, potent kinase inhibitors
    Patent number: 8067591
    Abstract: Pyrrole pyrazole compounds of formula I, compositions including these compounds and methods of their use are provided. Preferred compounds of formula I have activity as protein kinase inhibitors, including as inhibitors of PAK4.
    Type: Grant
    Filed: December 28, 2005
    Date of Patent: November 29, 2011
    Assignees: Agouron Pharmaceuticals, Inc., Pfizer Inc.
    Inventors: Junhu Zhang, Chuangxing Guo, Djamal Bouzida, Liming Dong, Haitao Li, Joseph Timothy Marakovits, Anle Yang, Yufeng Hong
  • Process for the production of benzopyran-2-ol derivatives
    Patent number: 8067594
    Abstract: The invention provides a process for producing a compound of formula (I), wherein Y is selected from the group consisting of CH3, CH2OH, CH2CH2OH, CH2Br and Br; comprising the steps of: (i) reacting a compound of formula (II), wherein OX represents hydroxy or O?M+, in which M+ is a cation selected from Li+, Na+ and K+, and Y is as defined above; with trans-cinnamaldehyde (III), in the presence of a secondary amine compound; then (ii) treating the product of the preceding step with acid to afford the compound of formula (I). The above process may also be used in the production of tolterodine and fesoterodine, which are useful in the treatment of overactive bladder.
    Type: Grant
    Filed: May 21, 2007
    Date of Patent: November 29, 2011
    Assignee: Pfizer Inc.
    Inventors: Jens Bertil Ahman, Barry Richard Dillon, Alan John Pettman
  • Heterocyclic compounds useful in treating diseases and conditions
    Patent number: 8067589
    Abstract: The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein the substituents are as defined herein, compositions containing such compounds and the uses of such compounds for the treatment of various diseases and conditions such as asthma.
    Type: Grant
    Filed: July 9, 2009
    Date of Patent: November 29, 2011
    Assignee: Pfizer Inc
    Inventors: Tanisha D. Blake, Bruce C. Hamper, Wei Huang, James R. Kiefer, Jr., Joseph B. Moon, Bradley E. Neal, Kirk L. Olson, Matthew J. Pelc, Barbara A. Schweitzer, Atli Thorarensen, John I. Trujillo, Steven R. Turner
  • Pyrrolo[2,3-d]Pyrimidine Derivatives; Their Intermediates and Synthesis
    Publication number: 20110288297
    Abstract: This invention relates to methods and intermediates useful for the synthesis of pyrrolo[2,3-d]pyrimidine compounds. Specifically novel synthetic methods and intermediates for the synthesis of 3-{(3R,4R)-4-methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino}-piperidin-1-yl)-3-oxo-propionitrile and its corresponding citrate salt are disclosed.
    Type: Application
    Filed: July 17, 2006
    Publication date: November 24, 2011
    Applicant: Pfizer, Inc.
    Inventors: Sally Gut Ruggeri, Joel M. Hawkins, Teresa M. Makowski, Jennifer L. Rutherford, Frank J. Urban
  • PARAPOXVIRUS VECTORS
    Publication number: 20110287051
    Abstract: The present invention relates to recombinant parapoxviruses which carry in their genomes comprising heterologous DNA derived from a rabies virus, to the preparation of such constructs, and to their use in immunogenic compositions and vaccines. It further relates to the use of recombinant parapoxviruses for diagnostics.
    Type: Application
    Filed: May 19, 2011
    Publication date: November 24, 2011
    Applicant: PFIZER INC.
    Inventors: Olivier Michel Martinon, Nanda Kumar D Reddy
  • Pyrazole derivatives
    Patent number: 8063044
    Abstract: This invention relates to pyrazole derivatives of formula (I) or pharmaceutically acceptable salts, solvates or derivative thereofs, wherein R1 to R4 are defined in the description, and to processes for the preparation thereof, intermediates used in their preparation of, compositions containing them and the uses of such derivatives. The compounds of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof. As such the compounds of the present invention are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodeficiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS).
    Type: Grant
    Filed: August 25, 2008
    Date of Patent: November 22, 2011
    Assignee: Pfizer Inc.
    Inventors: Lyn Howard Jones, Charles Eric Mowbray, David Anthony Price, Matthew Duncan Selby, Paul Anthony Stupple
  • ANTIBODIES TO CCR2
    Publication number: 20110274696
    Abstract: Provided are antibodies including human antibodies and antigen-binding portions thereof that specifically bind to CCR2, specifically human CCR2, and that may function to inhibit CCR2. Anti-CCR2 antibodies include those which bind to the first and/or second extracellular loops of CCR2. Also provided are human anti-CCR2 antibodies and antigen-binding portions thereof. Isolated heavy and light chain immunoglobulins derived from human anti-CCR2 antibodies and nucleic acid molecules encoding such immunoglobulins are provided. Methods of making human anti-CCR2 antibodies or antigen-binding portions, compositions comprising these antibodies or antigen-binding portions, methods of using the antibodies and antigen-binding portions, and compositions for diagnosis and treatment are provided.
    Type: Application
    Filed: August 17, 2009
    Publication date: November 10, 2011
    Applicants: AMGEN FREMONT INC., PFIZER INC.
    Inventors: Ronald P. Gladue, Bradley T. Keller, Shinji Ogawa, Arvind Rajpal, Laurie A. Tylaska, Shelley Sims Belouski, Larry L. Green, Meina Liang
  • Genetic Markers for Horned and Polled Cattle and Related Methods
    Publication number: 20110262909
    Abstract: Embodiments of the present invention provide methods for improving desirable animal traits including the horned/polled phenotype in bovine animals. Also provided are methods for determining a dairy animal's genotype with respect to multiple markers associated with polled, fitness and/or productivity traits. The invention also provides methods for selecting or allocating animals for predetermined uses such as progeny testing or nucleus herd breeding, for picking potential parent animals for breeding, and for producing improved progeny animals. Also provided are methods for identifying genetic markers associated with polled, fitness and/or productivity traits that are in allelic association with the SNPs disclosed herein.
    Type: Application
    Filed: September 24, 2008
    Publication date: October 27, 2011
    Applicant: Pfizer
    Inventors: Edward J. Cargill, Michael D. Grosz, Nicholas J. Nissing
  • Preparation of pregabalin and related compounds
    Patent number: 8044227
    Abstract: Materials and methods for preparing (S)-(+)-3-aminomethyl-5-methyl-hexanoic acid and structurally related compounds via enzymatic kinetic resolution are disclosed.
    Type: Grant
    Filed: November 22, 2010
    Date of Patent: October 25, 2011
    Assignee: Pfizer Inc.
    Inventors: Shanghui Hu, Carlos Alberto Martinez, Junhua Tao, William Eugene Tully, Patrick Kelleher, Yves Dumond
  • Biaryl ether urea compounds
    Patent number: 8044052
    Abstract: The present invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt thereof; processes for the preparation of the compounds; intermediates used in the preparation of the compounds; compositions containing the compounds; and uses of the compounds in treating diseases or conditions associated with fatty acid amide hydrolase (FAAH) activity.
    Type: Grant
    Filed: October 18, 2007
    Date of Patent: October 25, 2011
    Assignee: Pfizer Inc.
    Inventors: Lorraine Kathleen Fay, Douglas S. Johnson, Suzanne Ross Kesten, Scott E. Lazerwith, Mark Anthony Morris, Cory Michael Stiff, Marvin Jay Meyers, Lijuan Jane Wang
  • Alpha 5-beta 1 antibodies and their uses
    Patent number: 8039596
    Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, or antigen binding portions thereof, that specifically bind to integrin ?5?1 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies or antigen binding portions thereof are also provided. The disclosure also provides methods for treating various cancers using the anti-?5?1 antibodies or antigen binding portions thereof described herein.
    Type: Grant
    Filed: February 4, 2009
    Date of Patent: October 18, 2011
    Assignees: Bristol-Myers Squibb Company, Pfizer Inc.
    Inventors: Steven Lee Bender, Gerald Fries Casperson, Dana Dan Hu-Lowe, Xin Jiang, Gang Li, Michael Aidan North, Jianying Wang, Grant Wickman, Peter Brams, Haichun Huang, Brigitte Devaux, Haibin Chen, Dawn M. Tanamachi, Kristopher Toy, Lan Yang, Tim W. Sproul, Mark Yamanaka
  • SUBSTITUTED ISOXAZOLINE DERIVATIVES
    Publication number: 20110251247
    Abstract: This invention recites substituted isoxazoline derivatives of Formula (1) or a veterinarily acceptable salt thereof, with parasiticidal activity, compositions thereof, and their use as a parasiticide in animals or birds where R1a, R1b, R1c, R2, R3, and n are as described herein.
    Type: Application
    Filed: April 6, 2011
    Publication date: October 13, 2011
    Applicant: PFIZER INC.
    Inventors: Nathan Anthony Logan Chubb, Todd Maddux, Sanjay Menon